1Tomas C, Penttinen J, Risteli J, et al. Serum concentrations of CA125 and aminoterminal propeptide of type Ⅲ procollagen(PⅢNP) in patients with endometrial carcinoma. Cancer, 1990,66:2399-2406.
2Rose PG, Sommers RM, Reale FR, et al. Serial serum.CA125 measurement for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol, 1994,84:12-16.
3Sato K, Mizuuchi H, Mori Y, et al. Usefulness of CA125 deterrninatfion in the diagnosis of lymph node metastasis in post menopausal uterine endometrial carcinoma. Niploon Sanka Fujinka Gakkai Zasshi, 1944,46(4):331.
4Kim HS,Park NH,Chung HH,et al.Serum CA125level after 6cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders’survival in patients with advanced epithelial ovarian cancer[J].Onkologie,2008,31(6):315-320.
5Miller MC,DiSilvestro P,Brown AK,et al.A novel multiple marker bioassay utilizing HE 4and CA125for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecol Onco,2009,112(1):40-46.
